Anemia Anemia,
Conditions
Interventions
This group received Eprex (150 units/kg subcutaneously three times a week) and Ferrous sulfate (one tablet every 8 hours) for 6 weeks,This group received Eprex (150 units/kg subcutaneously three times
intravenously at each chemotherapy session)
Active Comparator Drug,Active Comparator Drug
Eprex and Ferrous sulfate ,Eprex and Venofer
Sponsors
Shahrekord University of Medical Sciences
Shahrekord University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The criteria for including the study were: anemia secondary to malignancy and chemotherapy, the patient's hemoglobin 1 to 4 degrees based on the NCI system, serum ferritin level lower than 15, the Karnofsky performance status scale (an assessment tool for functional impairment) greater than or equal to 70%, and in remission stage for those cases with hematological malignancies.
Exclusion criteria
Exclusion criteria: Those patients with the following criteria were excluded: anemia due to other causes than malignancy, suffering from digestive disorders caused by oral iron intake or gastrointestinal bleeding, gastric cancer, total gastrostomy, lack of response to more than 20% of questions in the questionnaire, unwillingness of the patient to continue cooperation during the study, serum ferritin level greater than 500, patient death due to complications of the illness or treatment during the study, banning from Eprex administration due to thromboembolic events and systolic blood pressure more than 160 mm Hg during the study or any infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life Before and after the completion of the study Using EORTC QLQ-C30, a standard questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin Before and after the completion of the study Glocometer | — |
Countries
Iran
Contacts
Public ContactHourieh Ansari
Shahrekord University of Medical Sciences
Outcome results
None listed